We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.

Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...

In terms of liquidity and interest, the mean open interest for McKesson options trades today is 166.17 with a total volume of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This often is a signal that the stock you are watching is weak. Waiting for a turn higher may be more intelligent than trying to catch a falling knife. In any case, new support levels are usually ...

Sen. Elizabeth Warren (D-Mass.) on Tuesday urged the Federal Trade Commission to block recently signed deals by medical distributors McKesson (NYSE:MCK) and Cardinal Health (NYSE:CAH) to acquire ...

The lowest intraday price it traded in the past year was $ ... which tend to lose value over time due to inflation. USA TODAY Blueprint may earn a commission from this advertiser.

MCKESSON CORP (MCK) is a large-cap growth stock in the Major Drugs industry. The rating using this strategy is 80% based on the firm’s underlying fundamentals and the stock’s valuation.

In other news, CEO Brian S. Tyler sold 3,753 shares of McKesson stock ... by insiders. MCK has been the topic of several recent analyst reports. Wells Fargo & Company cut their price target ...

Though most have underperformed in 2024, these 9 S&P 500 stocks offer a 5% dividend yield or better.